Petra Kaufmann - 18 Mar 2024 Form 4 Insider Report for Vigil Neuroscience, Inc. (VIGL)

Role
Chief Medical Officer
Signature
/s/ Christopher Verni, Attorney-in-Fact
Issuer symbol
VIGL
Transactions as of
18 Mar 2024
Net transactions value
$0
Form type
4
Filing time
20 Mar 2024, 16:07:04 UTC
Next filing
04 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIGL Stock Option Grant (Right to Buy) Award $0 +330,000 $0.000000 330,000 18 Mar 2024 Common Stock 330,000 $3.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option award was issued subject to the terms of the Issuer's 2021 Stock Option and Incentive Plan and shall vest as follows: 25% of the shares shall be vested on March 18, 2025 and 1/36th of the remaining shares shall vest on each monthly anniversary thereafter.